Why is Concord Drugs falling/rising?

As of 10-Nov, Concord Drugs Ltd is experiencing a price increase, with its current price at Rs. 77.75, reflecting a rise of 7.06 or 9.99%. The stock has reached a new 52-week high today and has outperformed its sector by 8.94%. Over the past week, the stock has shown a robust return of 16.03%, while its performance over the last year has been impressive at 107.33%. The company has also demonstrated strong fundamentals, with a return on capital employed (ROCE) of 5.3 and a PEG ratio of 0, indicating attractive valuation compared to its peers. Additionally, the stock is trading above its moving averages, and there has been a significant increase in investor participation, with delivery volume rising by 67.95% against the 5-day average.
In the broader market context, while Concord Drugs has been performing exceptionally well, the benchmark Sensex has seen a slight decline of 0.53% over the past week. This contrast highlights the stock's strong market-beating performance, particularly as it has outperformed the BSE500 over various time frames, including the last three years and one year. The stock's liquidity is also favorable, allowing for sufficient trading volume, which supports its upward price movement. Overall, the combination of strong returns, positive investor sentiment, and attractive valuation metrics contribute to the stock's rising price.